Making American medical manufacturing a national priority
The United States should never be dangerously dependent on foreign sources for the products that protect its healthcare workers, first responders, service members, and families.
AMMA brings domestic manufacturers together with policymakers, agencies, healthcare buyers, and industry partners to build a stronger medical industrial base. We advance practical, bipartisan policies that sustain American production in ordinary times and make it ready to scale when a crisis comes. That base does more than protect the country in an emergency. It supports skilled jobs, local economic growth, and stronger communities where American plants operate.
American plants are already making these products
AMMA member companies operate facilities from coast to coast, including California; Nebraska, Illinois, Michigan, and Ohio in the Midwest; New York and Connecticut in the East; and the Carolinas, Texas, and Louisiana in the South. These facilities produce critical medical supplies under U.S. labor and safety standards. Based on annual production capacity reported by AMMA member companies as of August 2026, this domestic base can deliver:
Billions of masks
Surgical and procedure masks produced on U.S. lines
Hundreds of millions of respirators and gowns
Including NIOSH-approved N95s and isolation apparel
3 billion needles and syringes
Essential devices for injections, medication delivery, and blood collection
5 billion nitrile gloves
Domestic nitrile capacity scalable to more than 31 billion with sustained demand
More than 90 percent of the medical gloves used in the United States are manufactured overseas, and similar vulnerabilities remain across other critical PPE categories. This dependence is not a limit on American capability. It is the result of purchasing and trade decisions, and those decisions can be changed.
Source: AMMA analysis of industry data, 2026. Production capacity reported by AMMA member companies, August 2026.
Growing the base means growing American communities
A medical manufacturing base is a national security asset. It is also a payroll, a supplier network, and a local tax base. Every production line operating in a U.S. plant supports skilled jobs in production, maintenance, quality assurance, engineering, and logistics. These are careers that sustain families, strengthen local economies, and create opportunities close to home.
Those jobs multiply. Domestic manufacturers buy resins, nonwovens, tooling, packaging, and equipment from other American suppliers, and they anchor the workforce pipelines, including apprenticeships, technical training, and community college partnerships, that let the next generation build a career close to home. When public and private buyers choose American-made medical supplies, the return arrives twice: a supply chain the country can count on, and lasting economic opportunity in the communities that host these facilities.
Preparedness starts before an emergency
Domestic capacity cannot be switched on after a supply chain breaks. Manufacturers need predictable demand, fair competition, access to investment, and purchasing policies that recognize the strategic value of making critical medical products in the United States.
AMMA turns the operating experience of American manufacturers into concrete policy. We work with Congress, the White House, federal agencies, state leaders, and private-sector buyers to make resilience part of everyday decision-making, not an emergency afterthought.
Five commitments we carry into every room
-
Buy American, consistently
Taxpayer-funded purchasing should strengthen the domestic capacity taxpayers rely on. AMMA advocates for full implementation and expansion of the Make PPE in America Act, clear domestic-content standards, consistent enforcement across agencies, and multi-year contracts that give manufacturers the confidence to invest.
-
Build steady demand and real preparedness
Boom-and-bust purchasing weakens the very factories the country needs in a crisis. We support predictable federal purchasing cycles, durable Strategic National Stockpile commitments, regional preparedness, and healthcare payment policies that reward hospitals and health systems for choosing American-made PPE and critical medical supplies.
-
Enforce fair and ethical trade
American manufacturers already compete against state subsidies, dumped goods, tariff evasion, transshipment, and products tied to forced labor. AMMA presses for targeted trade remedies, effective customs enforcement, and the closure of loopholes that reward unfair or abusive practices.
-
Invest in American capacity and innovation
Building a medical manufacturing base takes long-term capital. Building on the pro-growth tax provisions enacted in 2025, AMMA presses for access to financing, advanced-manufacturing investment, sustained research and development incentives, and domestic production of the raw materials and components that make the full supply chain more secure. Expanding that base supports new skilled jobs and broader economic opportunity in American communities.
-
Make quality and origin visible
Buyers should be able to identify products verified as meeting applicable U.S.-made standards. AMMA promotes transparent sourcing, trusted quality, and clear proof of origin, including the AMMA Certified USA Made Product seal, so public and private purchasing can support American workers with confidence.
AMMA Certified USA Made Product
The AMMA Certified USA Made Product seal gives public and private buyers a simple way to identify critical medical supplies and PPE verified as meeting applicable U.S.-made standards. Look for the seal when you buy.
Advancing Medicare support for American-made medical supplies
AMMA is working to make domestic sourcing a meaningful part of Medicare payment policy. Following its initial recommendations to CMS in March, AMMA submitted detailed comments on August 31 supporting separate Medicare payments for hospitals that purchase American-made PPE and essential medicines. AMMA called for clear domestic-origin standards, practical purchase verification, product-specific payments, and incentives strong enough to move hospital purchasing toward reliable American suppliers.
Experience from the plant floor, on the record in Washington
We bring manufacturers to the table
Through Washington fly-ins, briefings, workshops, and direct engagement, AMMA gives policymakers access to the people who build and operate America's medical manufacturing capacity.
We shape legislation and implementation
We work on bills, appropriations, procurement rules, reimbursement policy, tax policy, and agency implementation so that good intentions produce durable demand and measurable results.
We put evidence on the public record
AMMA submits regulatory comments, open letters, and industry data to HHS, CMS, Commerce, USTR, CBP, Congress, and the Administration.
We build coalitions and public awareness
We make domestic medical manufacturing a priority for public health, economic security, human rights, and national security. We drive media coverage and build a community online to drive the public conversation.
Wins, filings, and milestones
Building predictable federal demand for American-made PPE
AMMA has consistently pressed federal agencies to use their purchasing power to sustain American medical manufacturing. In September, HHS established its first recurring, department-wide forecast of anticipated PPE purchases, giving domestic manufacturers greater visibility into future demand. Effective October 1, HHS procurement policy also requires covered PPE purchases to be domestic, with limited exceptions, and establishes contract periods of at least two years. Together, these actions strengthen implementation of the Make PPE in America Act and give American manufacturers a clearer foundation for hiring, investment, and production.
Applying preparedness lessons to recurring emergencies
As wildfire smoke affected communities from the Midwest to the East Coast, AMMA publicly highlighted the need for dependable access to domestically manufactured, NIOSH-approved N95 respirators and a resilient American medical manufacturing base. These recurring emergencies reinforce why domestic capacity must be sustained before a crisis so American manufacturers are ready when communities need protection.
Winning action against forced-labor trade distortions
AMMA filed detailed Section 301 comments documenting domestic capacity and the national-security, market, and human-rights risks associated with overseas PPE supply chains. On July 23, USTR finalized Section 301 duties generally ranging from 10 to 12.5 percent on products from 60 economies in response to failures to prohibit or effectively enforce bans on forced-labor imports. AMMA called the action a long-sought victory and continues pressing for strong implementation and domestic purchasing commitments.
Confronting structural overcapacity and unfair trade
AMMA placed the impact of foreign structural overcapacity directly before federal trade officials. In formal Section 301 comments, AMMA documented how unfairly supported overseas production distorts the market, weakens American medical manufacturers, and threatens the domestic capacity the country needs during emergencies. AMMA also submitted evidence to the U.S. International Trade Commission on the consequences of China’s Permanent Normal Trade Relations status, strengthening the case for a trade policy that supports American production and supply-chain security.
Putting medical-supply dependence into the Section 232 record
AMMA welcomed Commerce's Section 232 investigation into imports of PPE, medical supplies, consumables, and equipment; mobilized manufacturers to provide capacity and vulnerability data; and submitted formal comments documenting the national-security risks of overreliance on foreign supply chains. AMMA continues to press for a final remedy that recognizes medical-supply dependence as a national-security risk and reflects America's existing domestic manufacturing capacity.
Restoring respirator-approval capacity at NIOSH
When critical cuts and layoffs threatened NIOSH and its National Personal Protective Technology Laboratory, AMMA helped lead the effort to protect the respirator-approval system, worker safety, and domestic innovation. AMMA members briefed policymakers, worked with industry allies and labor organizations, and spoke publicly about the consequences of losing these essential functions. Following sustained advocacy, critical positions and respirator-safety functions were restored. The renewed program approved 142 new respirators during the first half of 2026, demonstrating the importance of maintaining a strong and fully funded NIOSH.
Building momentum against transshipment and tariff evasion
AMMA has made stronger enforcement against transshipment, tariff evasion, and fraudulent trade practices a central federal priority. On August 31, the House passed H.R. 1869, the bipartisan Protecting American Industry and Labor from International Trade Crimes Act. The legislation would create a dedicated Justice Department structure to investigate and prosecute illegal transshipment, duty evasion, forced-labor violations, and related trade crimes. AMMA supported House passage and continues working to build support for final enactment.
Securing pro-growth domestic manufacturing provisions
AMMA welcomed enactment of permanent immediate expensing for domestic research and development, 100 percent bonus depreciation for equipment and facilities, a permanent Section 199A deduction, enacted de minimis reform, and new funding and policy direction for domestic reserves. These measures reflected priorities AMMA had urged Congress and the Administration to adopt.
Launching a trusted American-made seal
AMMA launched the AMMA Certified USA Made Product seal to help public and private buyers identify critical medical supplies and PPE verified as meeting applicable U.S.-made standards.
Setting a cross-government manufacturing agenda
In open letters and its federal policy priorities, AMMA called for full implementation of the Make PPE in America Act, stronger trade enforcement, expanded CMS incentives, sustained stockpile funding, immediate domestic R&D expensing, 100 percent bonus depreciation, a permanent Section 199A deduction, and a Medical Supply Security Tax Credit.
Winning stronger China Section 301 treatment for medical products
AMMA urged USTR to end outdated exclusions for Chinese-made medical supplies and give American manufacturers a fair opportunity to compete. USTR’s final China Section 301 action strengthened tariff treatment for face masks, medical gloves, needles, and syringes. The full strength of this victory took effect on January 1, 2026, when Section 301 duties increased to 50 percent on covered Chinese textile masks and respirators and 100 percent on covered Chinese medical and surgical gloves. These higher duties reinforce the fairer competitive conditions AMMA fought to secure for American manufacturers.
Broadening the alliance and keeping preparedness on Congress's agenda
Founded in 2021 as the American Mask Manufacturers Association, AMMA broadened in 2023 into an alliance of domestic PPE manufacturers, healthcare organizations, and supply-chain partners. Later that year, AMMA joined a coalition calling on Congress to reauthorize the Pandemic and All-Hazards Preparedness Act and sustain the domestic capacity built after COVID-19.
The outcomes we are working toward
- Federal agencies use clear Buy American rules and long-term contracts.
- Hospitals and health systems receive practical incentives to purchase American-made medical supplies.
- Stockpiles are adequately funded and replenished with high-quality American-made products.
- Trade enforcement counters circumvention, dumping, and competition built on forced labor.
- Manufacturers can access the capital and demand signals needed to operate, innovate, and scale.
- Policymakers and buyers treat domestic medical manufacturing as critical national infrastructure.
- A growing domestic base supports skilled jobs, local economic growth, and stronger American communities.
Add your voice to American manufacturing
Resilience is built through the choices government, healthcare, and industry make every day. Work with AMMA to secure America's supply of critical medical products, support skilled American jobs, and prepare the country before the next disruption.